Report of Foreign Issuer (6-k)
May 10 2019 - 4:24PM
Edgar (US Regulatory)
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2019
Commission File Number:
001-36697
DBV TECHNOLOGIES S.A.
(Translation of registrant’s name into English)
177-181
avenue Pierre Brossolette
92120 Montrouge France
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form
20-F
or Form
40-F:
☒ Form
20-F ☐ Form
40-F
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
EXHIBIT LIST
|
|
|
|
|
Exhibit
|
|
Description
|
|
|
|
|
99.1
|
|
Press Release dated May 3, 2019.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
DBV TECHNOLOGIES S.A.
|
|
|
|
|
|
|
Date: May 10, 2019
|
|
|
|
By:
|
|
/s/ David Schilansky
|
|
|
|
|
|
Name:
|
|
David Schilansky
|
|
|
|
|
|
Title:
|
|
Deputy Chief Executive Officer
|
Exhibit 99.1
|
|
|
|
|
|
Montrouge, France, May 3, 2019
|
Ordinary and Extraordinary General Meeting of May 24, 2019
Procedures for Obtaining Preparatory Documents for the General Meeting
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a
clinical-stage biopharmaceutical company, announced today that it will hold its Ordinary and Extraordinary General Meeting on May 24, 2019 at 8:30 a.m. CEST at the Company’s headquarters located at
177-181
Avenue Pierre Brossolette – 92120 Montrouge, France.
The
preliminary notice (
l’avis préalable
)
containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this meeting was published in the French
“Bulletin des Annonces
Légales Obligatoires
(BALO)” dated April 19, 2019. The notice of meeting (l’avis
de convocation)
stating the time and place of the meeting will be published in the BALO and in the Legal Gazette on May 6, 2019.
The preparatory documents for the General Meeting listed in article R.
225-73-1
of the French Commercial Code are posted on the Investors & Media section of the Company’s website located at:
https://www.dbv-technologies.com/investor-relations/financial-information/annual-reports/
The documents for the General Meeting will also be made available to shareholders as of the date of the issuance of the
convening notice. Thus, in accordance with applicable law and regulations:
|
|
•
|
Any shareholder holding registered shares may, until the fifth day prior to the General Meeting, request that the
Company send them the documents required under articles
L.225-115
and
R.225-83
of the French Commercial Code, electronically at their express request. For shareholders
holding bearer shares, the exercise of this right is subject to the submission of a certificate of participation in the bearer share accounts held by the authorized financial intermediary.
|
|
|
|
•
|
Any shareholder may consult the documents and information referred to in articles
L.225-115
and
R.225-83
of the French Commercial Code, which are available at the Company’s headquarters.
|
|
About DBV Technologies
DBV Technologies is developing Viaskin
®
, a proprietary
technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this
new class of self-administered and
non-invasive
product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s
food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human
proof-of-concept
clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other
immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the
Company’s ADSs (each representing
one-half
of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1
212-271-0740
sara.sherman@dbv-technologies.com
DBV Media Contact
Joe Becker
VP,
Global Corporate Communications
+1-646-650-3912
joseph.becker@dbv-technologies.com
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Apr 2023 to Apr 2024
